Core Viewpoint - The company announced early clinical research results for three cell cycle protein-dependent kinase inhibitors (CDKis) at the European Society for Medical Oncology (ESMO) annual meeting, highlighting its strategic focus in this area [1] Group 1: Clinical Research - The three CDK inhibitors presented are TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the ESMO 2025 annual meeting, which is a significant event in the oncology field [1] Group 2: Event Details - The ESMO 2025 annual meeting is scheduled to take place from October 17-21, 2025, in Berlin, Germany [1] - This meeting is recognized as one of the most influential academic gatherings in oncology, attracting top experts and scholars [1]
同源康医药-B：ESMO 2025年会公布多项CDK抑制剂临床积极数据